Covid19 Research

The James & Lillian Martin Centre at the Sir William Dunn School of Oxford oversees the core Containment level 3 Facility that supports work of the Centre and many collaborating groups, on SARS-CoV-2 and HIV-1. The following a some research publications that have resulted from this work

Immune responses to  SARS-CoV-2 infection and vaccines

Skelly, D.T., A.C. Harding, J. Gilbert-Jaramillo, M.L. Knight, S. Longet, A. Brown, S. Adele, et al. “Two Doses of SARS-CoV-2 Vaccination Induce Robust Immune Responses to Emerging SARS-CoV-2 Variants of Concern.” Nature Communications 12, no. 1 (2021).

Folegatti, Pedro M, Katie J Ewer, Parvinder Aley, Brian Angus, Stephan Becker, Sandra Belij-Rammerstorfer, Duncan Bellamy, et al. “Safety and Immunogenicity of the ChAdOx1 NCoV-19 Vaccine against SARS-CoV-2: A Preliminary Report of a Phase 1/2, Single-Blind, Randomised Controlled Trial.” The Lancet 396, no. 10249 (July 20, 2020): 467–78.

Peng, Y., S.L. Felce, D. Dong, F. Penkava, A.J. Mentzer, X. Yao, G. Liu, et al. “An Immunodominant NP<inf>105–113</Inf>-B*07:02 Cytotoxic T Cell Response Controls Viral Replication and Is Associated with Less Severe COVID-19 Disease.” Nature Immunology 23, no. 1 (2022): 50–61.

Huang, Kuan Ying A., Tiong Kit Tan, Ting Hua Chen, Chung Guei Huang, Ruth Harvey, Saira Hussain, Cheng Pin Chen, et al. “Breadth and Function of Antibody Response to Acute SARS-CoV-2 Infection in Humans.” Edited by Benhur Lee. PLoS Pathogens 17, no. 2 (February 26, 2021): e1009352.

Zhou, Daming, Wanwisa Dejnirattisai, Piyada Supasa, Chang Liu, Alexander J. Mentzer, Helen M. Ginn, Yuguang Zhao, et al. “Evidence of Escape of SARS-CoV-2 Variant B.1.351 from Natural and Vaccine Induced Sera.” Cell, February 23, 2021.

Huo, Jiandong, Halina Mikolajek, Audrey Le Bas, Jordan J. Clark, Parul Sharma, Anja Kipar, Joshua Dormon, et al. “A Potent SARS-CoV-2 Neutralising Nanobody Shows Therapeutic Efficacy in the Syrian Golden Hamster Model of COVID-19.” Nature Communications 2021 12:1 12, no. 1 (September 22, 2021): 1–18.

Supasa, P., D. Zhou, W. Dejnirattisai, C. Liu, A.J. Mentzer, H.M. Ginn, Y. Zhao, et al. “Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant by Convalescent and Vaccine Sera.” Cell 184, no. 8 (2021): 2201-2211.e7.

Zhou, D., H.M.E. Duyvesteyn, C.-P. Chen, C.-G. Huang, T.-H. Chen, S.-R. Shih, Y.-C. Lin, et al. “Structural Basis for the Neutralization of SARS-CoV-2 by an Antibody from a Convalescent Patient.” Nature Structural and Molecular Biology 27, no. 10 (2020): 950–58.

Mistry, P., F. Barmania, J. Mellet, K. Peta, A. Strydom, I.M. Viljoen, W. James, S. Gordon, and M.S. Pepper. “SARS-CoV-2 Variants, Vaccines, and Host Immunity.” Frontiers in Immunology 12 (2022).

Development of SARS-CoV-2-neutralizing Monoclonal antibodies, nanobodies and chimeric proteins

Huang, K.-Y.A., D. Zhou, T.K. Tan, C. Chen, H.M.E. Duyvesteyn, Y. Zhao, H.M. Ginn, et al. “Structures and Therapeutic Potential of Anti-RBD Human Monoclonal Antibodies against SARS-CoV-2.” Theranostics 27, no. 1 (2022): 1–17.

Qiang, M., P. Ma, Y. Li, H. Liu, A. Harding, C. Min, F. Wang, et al. “Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago.” Advanced Science 9, no. 1 (2022).

Girt, G.C., A. Lakshminarayanan, J. Huo, J. Dormon, C. Norman, B. Afrough, A. Harding, W. James, R.J. Owens, and J.H. Naismith. “The Use of Nanobodies in a Sensitive ELISA Test for SARS-CoV-2 Spike 1 Protein.” Royal Society Open Science 8, no. 9 (2021).

Huo, Jiangdong, Audrey Le Bas, Reinis R. Ruza, Helen M.E. Duyvesteyn, Halina Mikolajek, Tomas Malinauskas, Tiong Kit Tan, et al. “Neutralizing Nanobodies Bind SARS-CoV-2 Spike RBD and Block Interaction with ACE2.” Nature Structural and Molecular Biology, July 13, 2020, 1–9.

Miao, X., Y. Luo, X. Huang, S.M.Y. Lee, Z. Yuan, Y. Tang, L. Chen, et al. “A Novel Biparatopic Hybrid Antibody-ACE2 Fusion That Blocks SARS-CoV-2 Infection: Implications for Therapy.” MAbs 12, no. 1 (2020).

Molecular Cell Biology of SARS-CoV-2

Zhang, Peijun. “Correlative Multi-Scale Cryo-Imaging Unveils SARS-CoV-2 Assembly and Egress,” January 19, 2021.

Lee, J.Y., P.A.C. Wing, D.S. Gala, M. Noerenberg, A.I. Järvelin, J. Titlow, X. Zhuang, et al. “Absolute Quantitation of Individual SARS-CoV-2 RNA Molecules Provides a New Paradigm for Infection Dynamics and Variant Differences.” ELife 11 (2022).

Wing, Peter A.C., Thomas P. Keeley, Xiaodong Zhuang, Jeffrey Y. Lee, Maria Prange-Barczynska, Senko Tsukuda, Sophie B. Morgan, et al. “Hypoxic and Pharmacological Activation of HIF Inhibits SARS-CoV-2 Infection of Lung Epithelial Cells.” Cell Reports 35, no. 3 (2021).

Dejnirattisai, W., D. Zhou, H.M. Ginn, H.M.E. Duyvesteyn, P. Supasa, J.B. Case, Y. Zhao, et al. “The Antigenic Anatomy of SARS-CoV-2 Receptor Binding Domain.” Cell 184, no. 8 (2021): 2183-2200.e22.

Matthews, P.C., M.I. Andersson, C.V. Arancibia-Carcamo, K. Auckland, J.K. Baillie, E. Barnes, T. Beneke, et al. “SARS-CoV-2 RNA Detected in Blood Products from Patients with COVID-19 Is Not Associated with Infectious Virus.” Wellcome Open Research 5 (2020).

Our evaluation of the neutralizing potency of the plasma from the Oxford-AstraZeneca Phase I trial against SARS-CoV-2 (Folegatti et al Lancet 2020 396: 467-78. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial)